Athira Pharma GudangMovies21 Rebahinxxi LK21

    Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
    The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
    Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer.


    History


    The company has received financial support from venture capitalist groups and angel investors through four rounds of funding to date. Athira Pharma was known as M3 Biotechnology until it underwent a name change on April 11, 2019.


    Core technology


    The company's lead asset, ATH-1017, is in human trials of Alzheimer's disease as of 2021. ATH-1017 is a small molecule therapeutic specifically designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, which are expressed in normal central nervous system function. It aims to regenerate lost connections in the brain, protect brain cells from further damage, and prevent additional neuronal deterioration. ATH-1017 is currently being tested in two clinical studies: ACT-AD and LIFT-AD.


    References




    External links


    Official website

Kata Kunci Pencarian:

athira pharma incathira pharmacyathira pharmaathira pharma stockathira pharma newsathira pharma aktieathira pharma stock forecastathira pharma inc stockathira pharma falsified research settlementathira pharma pipeline
Athira Pharma

Athira Pharma

Athira Pharma Culture | Comparably

Athira Pharma Culture | Comparably

Athira Pharma Culture | Comparably

Athira Pharma Culture | Comparably

Athira Pharma logo in transparent PNG and vectorized SVG formats

Athira Pharma logo in transparent PNG and vectorized SVG formats

Athira Pharma logo in transparent PNG and vectorized SVG formats

Athira Pharma logo in transparent PNG and vectorized SVG formats

Athira Pharma logo in transparent PNG and vectorized SVG formats

Athira Pharma logo in transparent PNG and vectorized SVG formats

Athira Pipeline_2022June – Athira Pharma

Athira Pipeline_2022June – Athira Pharma

Athira Pharma Jobs | Levels.fyi

Athira Pharma Jobs | Levels.fyi

Athira Pharma logo in transparent PNG and vectorized SVG formats

Athira Pharma logo in transparent PNG and vectorized SVG formats

Athira Pharma, Inc. - Prism MarketView

Athira Pharma, Inc. - Prism MarketView

Patients – Athira Pharma

Patients – Athira Pharma

Patients – Athira Pharma

Patients – Athira Pharma

Search Results

athira pharma

Daftar Isi

Athira Pharma

Dec 6, 2024 · Our novel small molecule compounds are designed to act on a naturally occurring repair system to promote regeneration, provide neuroprotection, and potentially modify …

News - Athira Pharma

Dec 6, 2024 · Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)

About - Athira Pharma

We are a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. At Athira, we are committed to restoring, …

Athira Pharma - Wikipedia

Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases …

Athira Pharma, Inc. (ATHA) - Yahoo Finance

Find the latest Athira Pharma, Inc. (ATHA) stock quote, history, news and other vital information to help you with your stock trading and investing.

Athira Pharma Announces Topline Results from Phase 2/3 LIFT …

BOTHELL, Wash., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small …

Athira Pharma to Present Results from Phase 2/3 LIFT-AD …

Athira is conducting a first-in-human Phase 1 (NCT 06432647) double-blind, placebo-controlled trial that is enrolling up to 80 healthy volunteers. The study is evaluating the safety and...

Athira Pharma Inc. Agrees to Pay $4M to Settle False Claims Act ...

Jan 6, 2025 · Athira Pharma Inc., located in Bothwell, Washington, has agreed to pay $4,068,698 to resolve allegations that it violated the False Claims Act (FCA) by failing to report allegations …

Athira Pharma Announces Publication in Frontiers in …

Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health …

Pipeline – Athira Pharma

We have designed our proprietary drug discovery platform to develop novel therapeutic candidates that offer the potential to impact a wide range of neurological diseases and conditions.